Libtayo® (cemiplimab for injection) Now Reimbursed in Seven Provinces for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...
TipRanks on MSN

Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a significant clinical ...
TipRanks on MSN

Akeso, Inc. Launches Promising Phase III Study for Lung Cancer Treatment

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. has announced a new clinical study titled ‘A ...

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 ...
Cancer Therapy Advisor

Tiragolumab-Atezolizumab Does Not Improve Survival Over Durvalumab in NSCLC

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.
ascopubs.org

Health state utility assessment for low-grade glioma.

Convolutional neural network and glioma genotyping: A systematic review. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.